We are taking on infectious diseases with the hope of creating a better world.
Our decades of research in infectious diseases have led to profound scientific advances
We've been combating global health threats caused by infectious diseases for more than a century. From developing one of the first antibiotics to pioneering research in HIV science, our focus has always been on the prevention and treatment of diseases that threaten people and communities around the world. But our work is far from done.
Every year, millions of people die from infectious diseases. The world is counting on us to bring forward new approaches to help ease human suffering.
Our work in infectious diseases
years committed to research to help combat the challenges of the HIV epidemic
the year we began producing penicillin "G"
investigator-initiated antimicrobial stewardship programs funded across the globe
Our legacy in innovative HIV science continues
We remember when HIV was one of society's most daunting challenges, when millions of people lost their lives to the devastating AIDS epidemic. Our scientists embarked on an urgent mission to unravel and understand the virus, which led to groundbreaking research in HIV.
We are still driven to do more. We are pushing the boundaries of HIV science because unmet medical need still endures. Eradication of the virus is our ultimate goal.
Continuing research and striving for improvements in the use of antibiotics
While other companies pull away from antibiotic research and development, we stand out from the pack. We continue our efforts, because we know the world needs it.
Joining a partnership to combat a deadly virus
Since the emergence of the Ebola virus in 1976, periodic outbreaks have been a global health challenge. We are proud to be part of the global public-private partnership that has united government, industry, community groups, scientists, health care workers and ordinary people, to come together to help fight this deadly disease.
The people and programs that are helping to combat infectious diseases
Explore the ways we are focusing our efforts on research in infectious disease.
The Ebola outbreak centered in the eastern region of the Democratic Republic of Congo has come to an end
The Ebola outbreak centered in the eastern region of the Democratic Republic of Congo has come to an end. Merck recognizes that the global collaboration and partnerships formed to take on this outbreak were critical and similar efforts are essential today in the midst of the COVID-19 pandemic and will continue to be in the […]
Lessons from dual pandemics
A conversation with Merck Chief Patient Officer Julie Gerberding, M.D., M.P.H., about her early work caring for people with HIV and AIDS, and the parallels of the AIDS and COVID-19 pandemics
Addressing antibiotic resistance is more critical than ever. Here’s why.
Since their development, antibiotics have transformed health care and saved countless lives globally. But rising levels of antimicrobial resistance (AMR) make current antibiotics less effective. There’s no single or simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get much-needed antibiotics to those […]
Our commitment to patients is unwavering
As long as there are still patients in hospitals, doctors desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here: fighting with all we have to deliver more, sooner.